comparemela.com

Latest Breaking News On - Hedge funds weigh in on eyepoint pharmaceuticals - Page 2 : comparemela.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $24.40

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $24.40
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Darioa-paggiarino
Toth-financial-advisory-corp
Investment-advisers
Nasdaq
Jpmorgan-chase-co
Insider-activity-at-eyepoint-pharmaceuticals
News-ratings-for-eyepoint-pharmaceuticals-daily
Tower-research-capital
Eyepoint-pharmaceuticals-stock-down
Schonfeld-strategic-advisors
Eyepoint-pharmaceuticals

EyePoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) issued its earnings results on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27, Zacks reports. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $8.71 million. EyePoint Pharmaceuticals had a negative return […]

Darioa-paggiarino
Hedge-funds-weigh-in-on-eyepoint-pharmaceuticals
Eyepoint-pharmaceuticals-inc
Eyepoint-pharmaceuticals-price-performance
Earnings-history-for-eyepoint-pharmaceuticals
Exome-asset-management
Voloridge-investment-management
News-ratings-for-eyepoint-pharmaceuticals-daily
Vanguard-group-inc
Jpmorgan-chase-co
Barclays-plc

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $33.86 Average PT from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has been assigned an average rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last […]

China
Darioa-paggiarino
Eyepoint-pharmaceuticals-inc
Toth-financial-advisory-corp
Jpmorgan-chase-co
Tower-research-capital
Nasdaq
Eyepoint-pharmaceuticals
Eyepoint-pharmaceuticals-price-performance
News-ratings-for-eyepoint-pharmaceuticals-daily
Us-bancorp

EyePoint Pharmaceuticals (NASDAQ:EYPT) Coverage Initiated at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) in a report issued on Monday, MarketBeat reports. The firm set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 40.51% from the […]

Eyepoint-pharmaceuticals-company-profile
Insider-activity-at-eyepoint-pharmaceuticals
Schonfeld-strategic-advisors
Barclays-plc
Eyepoint-pharmaceuticals-price-performance
News-ratings-for-eyepoint-pharmaceuticals-daily
Analyst-recommendations-for-eyepoint-pharmaceuticals
Securities-exchange-commission
Toth-financial-advisory-corp
Hedge-funds-weigh-in-on-eyepoint-pharmaceuticals
Investment-advisers

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock […]

Insider-transactions-at-eyepoint-pharmaceuticals
Schonfeld-strategic-advisors
Toth-financial-advisory-corp
News-ratings-for-eyepoint-pharmaceuticals-daily
Barclays-plc
Nasdaq
Eyepoint-pharmaceuticals
Cantor-fitzgerald
Lazard-asset-management
Eyepoint-pharmaceuticals-inc
Tower-research-capital

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.